FLCCC Alliance Announces Its First Groundbreaking Study to Determine Efficacy of Repurposed Drugs in Treating Cancer

A team of U.S. clinicians will participate in an observational study to determine improvements in the five-year survival rate for several types of cancer

WASHINGTON, D.C. – Today, at their sold-out education conference, the FLCCC Alliance announced that it has partnered with renowned breast cancer physician and researcher Kathleen Ruddy, MD, to conduct an observational study in five U.S. clinics to track patient responses to various adjunct cancer therapies using repurposed drugs and determine improvements in the five-year survival rate to several types of cancer including breast, prostate, lung, and colorectal.

More people than ever will be diagnosed with cancer this year, according to the American Cancer Society. Conventional cancer treatments have succeeded in preventing more than 4 million deaths from cancer since 1991. However, emerging research continues to demonstrate that more can be done using treatment regimens that include well-studied repurposed drugs.

“We hope that our research will bring attention to often overlooked methods for treating cancer as well as managing the symptoms from conventional treatment,” said Paul E. Marik, M.D., FCCM, FCCP, lead author of the study, chief scientific officer of the FLCCC and former Chief, Pulmonary and Critical Care Medicine at Eastern Virginia Medical School. “Our research is intended to advance a better understanding of how cancer can be treated more efficiently, with fewer side effects, through using well-studied approaches that include readily available medications that are well-studied and known to have minimal side effects.”

The final study results will focus on improvements in the five-year survival rate of certain cancers and include patients from five clinics nationwide that will collaborate and share anonymous patient information in a centralized collection tool where the data will be tracked and analyzed.

“Cancer continues to increase at an alarming rate, especially among younger populations, creating an imminent public health crisis,” said Kathleen Ruddy, MD, founder of the New Jersey-based practice Breast Health and Healing. “For over a year, I have been observing and advising 50 patients using a variety of repurposed treatments in the regimen, with some having remarkable results. More is to be learned, so I am excited to partner with the FLCCC on this new research.”

The five clinics participating in the study are:

Breast Health and Healing, led by Kathleen Ruddy, MD.
Leading Edge Clinic, led by Pierre Kory, MD, MPA and Scott Marsland, FNP-C
Brio Medical, a holistic, integrative cancer healing center, led by Nathan Goodyear, MD
Meakin Metabolic Care, led by Charles Meakin, MD
James Clinic, led by Mollie James, MD

The FLCCC Alliance published its Cancer Care Monograph in June 2023. A copy of the monograph can be found here: https://covid19criticalcare.com/reviews-and-monographs/cancer-care/

About the FLCCC Alliance

The FLCCC Alliance was organized in March 2020 by a group of highly published, world renowned critical care physicians and scholars with the academic support of allied physicians from around the world. FLCCC’s goal is to research and develop lifesaving protocols for the prevention and treatment of COVID-19 in all stages of illness including the I-RECOVER protocols for “Long COVID” and Post Vaccine Syndrome. For more information: www.FLCCC.net

###